Full Bayesian models to handle missing values in cost-effectiveness analysis from individual level data

#### Gianluca Baio

(Joint work with Andrea Gabrio and Alexina Mason)

University College London Department of Statistical Science

g.baio@ucl.ac.uk


http://www.ucl.ac.uk/statistics/research/statistics-health-economics/ http://www.statistica.it/gianluca https://github.com/giabaio


> RSS 2017 International Conference University of Strathclyde, Glasgow


Wednesday 6 September 2017



- Estimates relevant population parameters θ
- Varies with the type of available data (& statistical approach!)







		Den	nograp	hics		HRQL	data		Re	source ı	ıse da	ta
ID	Trt	Sex	Age		$u_0$	$u_1$		$u_J$	$c_0$	$c_1$		$c_J$
1	1	М	23		0.32	0.66		0.44	103	241		80
2	1	М	21		0.12	0.16		0.38	1 204	1 808		877
3	2	F	19		0.49	0.55		0.88	16	12		22

		Den	nograp	hics		HRQL	data		Re	source ı	ise da	ta
ID	Trt	Sex	Age		$u_0$	$u_1$		$u_J$	$c_0$	$c_1$		$c_J$
1	1	М	23		0.32	0.66		0.44	103	241		80
2	1	Μ	21		0.12	0.16		0.38	1 204	1 808		877
3	2	F	19		0.49	0.55		0.88	16	12		22

and the typical analysis is based on the following steps:

Compute individual QALYs and total costs as

$$e_i = \sum_{j=1}^J \left( u_{ij} + u_{ij-1} \right) \frac{\delta_j}{2} \quad \text{and} \quad c_i = \sum_{j=0}^J c_{ij}, \qquad \left[ \text{with: } \delta_j = \frac{\mathsf{Time}_j - \mathsf{Time}_{j-1}}{\mathsf{Unit of time}} \right]$$

		Den	nograp	hics		HRQL	data		Re	source ı	ıse da	ta
ID	Trt	Sex	Age		$u_0$	$u_1$		$u_J$	$c_0$	$c_1$		$c_J$
1	1	М	23		0.32	0.66		0.44	103	241		80
2	1	М	21		0.12	0.16		0.38	1 204	1 808		877
3	2	F	19		0.49	0.55		0.88	16	12		22

and the typical analysis is based on the following steps:

Compute individual QALYs and total costs as

$$e_i = \sum_{j=1}^J \left( u_{ij} + u_{ij-1} \right) \frac{\delta_j}{2} \quad \text{and} \quad c_i = \sum_{j=0}^J c_{ij}, \qquad \left[ \text{with: } \delta_j = \frac{\mathsf{Time}_j - \mathsf{Time}_{j-1}}{\mathsf{Unit of time}} \right]$$

Often implicitly) assume normality and linearity and model independently individual QALYs and total costs by controlling for baseline values

$$\begin{array}{lll} e_i &=& \alpha_{e0} + \alpha_{e1} u_{0i} + \alpha_{e2} \mathsf{Trt}_i + \varepsilon_{ei} \, [+ \dots], & \varepsilon_{ei} \sim \mathsf{Normal}(0, \sigma_e) \\ c_i &=& \alpha_{c0} + \alpha_{c1} c_{0i} + \alpha_{c2} \mathsf{Trt}_i + \varepsilon_{ci} \, [+ \dots], & \varepsilon_{ci} \sim \mathsf{Normal}(0, \sigma_c) \end{array}$$

		Den	nograp	hics		HRQL	data		Re	source ı	ıse da	ta
ID	Trt	Sex	Age		$u_0$	$u_1$		$u_J$	$c_0$	$c_1$		$c_J$
1	1	М	23		0.32	0.66		0.44	103	241		80
2	1	Μ	21		0.12	0.16		0.38	1 204	1 808		877
3	2	F	19		0.49	0.55		0.88	16	12		22

and the typical analysis is based on the following steps:

Compute individual QALYs and total costs as

$$e_i = \sum_{j=1}^J \left( u_{ij} + u_{ij-1} \right) \frac{\delta_j}{2} \quad \text{and} \quad c_i = \sum_{j=0}^J c_{ij}, \qquad \left[ \text{with: } \delta_j = \frac{\mathsf{Time}_j - \mathsf{Time}_{j-1}}{\mathsf{Unit of time}} \right]$$

Often implicitly) assume normality and linearity and model independently individual QALYs and total costs by controlling for baseline values

$$\begin{array}{lll} e_i & = & \alpha_{e0} + \alpha_{e1}u_{0i} + \alpha_{e2}\mathsf{Trt}_i + \varepsilon_{ei} \, [+ \dots], & & \varepsilon_{ei} \sim \mathsf{Normal}(0, \sigma_e) \\ c_i & = & \alpha_{c0} + \alpha_{c1}c_{0i} + \alpha_{c2}\mathsf{Trt}_i + \varepsilon_{ci} \, [+ \dots], & & \varepsilon_{ci} \sim \mathsf{Normal}(0, \sigma_c) \end{array}$$

Stimate population average cost and effectiveness differentials and use bootstrap to quantify uncertainty


Gianluca Baio (UCL)

- Potential correlation between costs & clinical benefits
  - Strong positive correlation effective treatments are innovative and result from intensive and lengthy research  $\Rightarrow$  are associated with higher unit costs
  - Negative correlation more effective treatments may reduce total care pathway costs e.g. by reducing hospitalisations, side effects, etc.
  - NB: In any case, the economic evaluation is based on both!

- Potential correlation between costs & clinical benefits
  - Strong positive correlation effective treatments are innovative and result from intensive and lengthy research  $\Rightarrow$  are associated with higher unit costs
  - Negative correlation more effective treatments may reduce total care pathway costs e.g. by reducing hospitalisations, side effects, etc.
  - NB: In any case, the economic evaluation is based on both!
- Joint/marginal normality not realistic
  - Costs usually skewed and benefits may be bounded in [0;1]
  - Can use transformation (e.g. logs) but care is needed when back transforming to the natural scale
  - Can use more suitable models (e.g. Gamma or log-Normal) especially under the Bayesian approach

- Potential correlation between costs & clinical benefits
  - Strong positive correlation effective treatments are innovative and result from intensive and lengthy research  $\Rightarrow$  are associated with higher unit costs
  - Negative correlation more effective treatments may reduce total care pathway costs e.g. by reducing hospitalisations, side effects, etc.
  - NB: In any case, the economic evaluation is based on both!
- Joint/marginal normality not realistic
  - Costs usually skewed and benefits may be bounded in [0;1]
  - Can use transformation (e.g. logs) but care is needed when back transforming to the natural scale
  - Can use more suitable models (e.g. Gamma or log-Normal) especially under the Bayesian approach
- ... and of course Partially Observed data
  - Can have item and/or unit non-response
  - Missingness may occur in either or both benefits/costs
  - The missingness mechanisms may also be correlated
  - Focus in decision-making not inference!

# To be or not to be (Bayesians)?...






# To be or not to be (Bayesians)?...

• In general, can represent a joint distribution as a conditional regression

 $p(e,c) = p(e)p(c \mid e) = p(c)p(e \mid c)$ 

# To be or not to be (Bayesians)?...




$$c_{i} \sim p(c \mid e, \phi_{ci}, \psi_{c})$$


$$g(\phi_{ci}) = \mu_{c} + \beta(e_{i} - \mu_{e}) [+ \dots]$$


$$\phi_{ci} = \text{location}$$

$$\psi_{c} = \text{ancillary}$$


$$\begin{array}{c} \text{Conditional model for } c \\ \hline \text{Marginal model for } e \\ \hline \text{Marginal model for e \\ \hline \text{$$








• Combining "modules" and fully characterising uncertainty about deterministic functions of random quantities is relatively straightforward using MCMC



- Combining "modules" and fully characterising uncertainty about deterministic functions of random quantities is relatively straightforward using MCMC
- Prior information can help stabilise inference (especially with sparse data!), eg
  - Cancer patients are unlikely to survive as long as the general population
  - ORs are unlikely to be greater than  $\pm 5$

Gianluca Baio (UCL)

MCAR(e, c)




Partially observed data

Unobservable parameters
 Deterministic function of random quantities

- Fully observed, unmodelled data
- Fully observed, modelled data
- $m_{ei} \sim \text{Bernoulli}(\pi_{ei});$
- $m_{ci} \sim \text{Bernoulli}(\pi_{ci});$

 $logit(\pi_{ei}) = \gamma_{e0}$  $logit(\pi_{ci}) = \gamma_{c0}$ 


MAR (e, c)



- Partially observed data
- Unobservable parameters
- Deterministic function of random quantities
- Fully observed, unmodelled data
- Fully observed, modelled data

•  $m_{ei} \sim \text{Bernoulli}(\pi_{ei});$   $\log it(\pi_{ei}) = \gamma_{e0} + \sum_{k=1}^{K} \gamma_{ek} x_{eik}$ •  $m_{ci} \sim \text{Bernoulli}(\pi_{ci});$   $\log it(\pi_{ci}) = \gamma_{c0} + \sum_{b=1}^{H} \gamma_{cb} x_{cib}$ 


MNAR (e, c)



- Partially observed data
- Unobservable parameters
- Deterministic function of random quantities
- Fully observed, unmodelled data
- Fully observed, modelled data

•  $m_{ei} \sim \text{Bernoulli}(\pi_{ei});$   $\text{logit}(\pi_{ei}) = \gamma_{e0} + \sum_{k=1}^{K} \gamma_{ek} x_{eik} + \gamma_{eK+1} e_i$ •  $m_{ci} \sim \text{Bernoulli}(\pi_{ci});$   $\log it(\pi_{ci}) = \gamma_{c0} + \sum_{b=1}^{H} \gamma_{cb} x_{cib} + \gamma_{cH+1} c_i$ 


#### MNAR e; MAR c



- Partially observed data
- Unobservable parameters
- O Deterministic function of random quantities
- Fully observed, unmodelled data
- Fully observed, modelled data

•  $m_{ei} \sim \text{Bernoulli}(\pi_{ei});$   $\log it(\pi_{ei}) = \gamma_{e0} + \sum_{k=1}^{K} \gamma_{ek} x_{eik} + \gamma_{eK+1} e_i$ •  $m_{ci} \sim \text{Bernoulli}(\pi_{ci});$   $\log it(\pi_{ci}) = \gamma_{c0} + \sum_{h=1}^{H} \gamma_{ch} x_{cih}$ 

MAR e; MNAR c



- Partially observed data
- Unobservable parameters
- O Deterministic function of random quantities
- Fully observed, unmodelled data
- Fully observed, modelled data

•  $m_{ei} \sim \text{Bernoulli}(\pi_{ei});$   $\log it(\pi_{ei}) = \gamma_{e0} + \sum_{k=1}^{K} \gamma_{ek} x_{eik}$ •  $m_{ci} \sim \text{Bernoulli}(\pi_{ci});$   $\log it(\pi_{ci}) = \gamma_{c0} + \sum_{k=1}^{H} \gamma_{ch} x_{cih} + \gamma_{cH+1} c_i$ 

- The MenSS pilot RCT evaluates the cost-effectiveness of a new digital intervention to reduce the incidence of STI in young men with respect to the SOC
  - QALYs calculated from utilities (EQ-5D 3L)
  - Total costs calculated from different components (no baseline)

- The MenSS pilot RCT evaluates the cost-effectiveness of a new digital intervention to reduce the incidence of STI in young men with respect to the SOC
  - QALYs calculated from utilities (EQ-5D 3L)
  - Total costs calculated from different components (no baseline)


Time	Type of outcome	observed (%)	observed (%)
		Control $(n_1=75)$	Intervention $(n_2=84)$
Baseline	utilities	72 (96%)	72 (86%)
3 months	utilities and costs	34 (45%)	23 (27%)
6 months	utilities and costs	35 (47%)	23 (27%)
12 months	utilities and costs	43 (57%)	36 (43%)
Complete cases	utilities and costs	27 (44%)	19 (23%)

- The MenSS pilot RCT evaluates the cost-effectiveness of a new digital intervention to reduce the incidence of STI in young men with respect to the SOC
  - QALYs calculated from utilities (EQ-5D 3L)
  - Total costs calculated from different components (no baseline)

RSS-pics.pdf	RSS-pics.pdf
RSS-pics.pdf	RSS-pics.pdf

#### Bivariate Normal

- Simpler and closer to "standard" frequentist model
- Account for correlation between QALYs and costs




#### Bivariate Normal

- Simpler and closer to "standard" frequentist model
- Account for correlation between QALYs and costs

#### 8 Beta-Gamma

- Account for correlation between outcomes
- Model the relevant ranges:  $\mathsf{QALYs} \in (0,1)$  and  $\mathsf{costs} \in (0,\infty)$
- But: needs to rescale observed data  $e_{it}^* = (e_{it} \epsilon)$  to avoid spikes at 1



### Bivariate Normal


- Simpler and closer to "standard" frequentist model
- Account for correlation between QALYs and costs

### eta-Gamma

- Account for correlation between outcomes
- Model the relevant ranges:  $\mathsf{QALYs} \in (0,1)$  and  $\mathsf{costs} \in (0,\infty)$
- But: needs to rescale observed data  $e^*_{it} = (e_{it} \epsilon)$  to avoid spikes at 1

### Hurdle model

- Model  $e_{it}$  as a **mixture** to account for correlation between outcomes, model the relevant ranges and account for structural values
- May expand to account for partially observed baseline utility  $u_{0it}$



Gianluca Baio (UCL)

#### Bivariate Normal


- Simpler and closer to "standard" frequentist model
- Account for correlation between QALYs and costs

### eta-Gamma

- Account for correlation between outcomes
- Model the relevant ranges:  $\mathsf{QALYs} \in (0,1)$  and  $\mathsf{costs} \in (0,\infty)$
- But: needs to rescale observed data  $e^*_{it} = (e_{it} \epsilon)$  to avoid spikes at 1

### Hurdle model

- Model  $e_{it}$  as a **mixture** to account for correlation between outcomes, model the relevant ranges and account for structural values
- May expand to account for partially observed baseline utility  $u_{0it}$



### Bivariate Normal


- Simpler and closer to "standard" frequentist model
- Account for correlation between QALYs and costs

### eta-Gamma


- Account for correlation between outcomes
- Model the relevant ranges:  $\mathsf{QALYs} \in (0,1)$  and  $\mathsf{costs} \in (0,\infty)$
- But: needs to rescale observed data  $e^*_{it} = (e_{it} \epsilon)$  to avoid spikes at 1

### Hurdle model

- Model  $e_{it}$  as a **mixture** to account for correlation between outcomes, model the relevant ranges and account for structural values
- May expand to account for partially observed baseline utility  $u_{0it}$




### Results — estimation of the main parameters (CCA + MAR)




Fully observed
 All (MAR)

### Results — estimation of the main parameters (CCA + MAR)




#### Bayesian multiple imputation (under MAR)




Imputed, observed baseline
 Imputed, missing baseline
 X Observed

## Bayesian multiple imputation (under MAR)



Imputed, observed baseline
 Imputed, missing baseline
 X Observed

## Bayesian multiple imputation (under MAR)



- We observe  $n_{01}=13$  and  $n_{02}=22$  individuals with  $u_{0it}=1$  and  $u_{jit}={\sf NA},$  for j>1
- For those individuals, we cannot compute directly the structural one indicator  $d_{it}$  and so need to make assumptions/model this
  - Sensitivity analysis to alternative MNAR departures from MAR

- We observe  $n_{01} = 13$  and  $n_{02} = 22$  individuals with  $u_{0it} = 1$  and  $u_{jit} =$  NA, for j > 1
- For those individuals, we cannot compute directly the structural one indicator  $d_{it}$  and so need to make assumptions/model this
  - Sensitivity analysis to alternative MNAR departures from MAR

MNAR1. Set  $d_{it} = 1$  for all individuals with unit observed baseline utility

- We observe  $n_{01} = 13$  and  $n_{02} = 22$  individuals with  $u_{0it} = 1$  and  $u_{jit} =$  NA, for j > 1
- For those individuals, we cannot compute directly the structural one indicator  $d_{it}$  and so need to make assumptions/model this
  - Sensitivity analysis to alternative MNAR departures from MAR

MNAR1. Set  $d_{it} = 1$  for all individuals with unit observed baseline utility MNAR2. Set  $d_{it} = 0$  for all individuals with unit observed baseline utility


- We observe  $n_{01}=13$  and  $n_{02}=22$  individuals with  $u_{0it}=1$  and  $u_{jit}={\sf NA},$  for j>1
- For those individuals, we cannot compute directly the structural one indicator  $d_{it}$  and so need to make assumptions/model this
  - Sensitivity analysis to alternative MNAR departures from MAR


MNAR1. Set  $d_{it} = 1$  for all individuals with unit observed baseline utility MNAR2. Set  $d_{it} = 0$  for all individuals with unit observed baseline utility MNAR3. Set  $d_{it} = 1$  for the  $n_{01} = 13$  individuals with  $u_{0i1} = 1$  and  $d_{it} = 0$  for the  $n_{02} = 22$  individuals with  $u_{0i2} = 1$ 

- We observe  $n_{01}=13$  and  $n_{02}=22$  individuals with  $u_{0it}=1$  and  $u_{jit}={\sf NA},$  for j>1
- For those individuals, we cannot compute directly the structural one indicator  $d_{it}$  and so need to make assumptions/model this
  - Sensitivity analysis to alternative MNAR departures from MAR

MNAR1. Set  $d_{it} = 1$  for all individuals with unit observed baseline utility

- MNAR2. Set  $d_{it} = 0$  for all individuals with unit observed baseline utility
- MNAR3. Set  $d_{it} = 1$  for the  $n_{01} = 13$  individuals with  $u_{0i1} = 1$  and  $d_{it} = 0$  for the  $n_{02} = 22$  individuals with  $u_{0i2} = 1$
- MNAR4. Set  $d_{it} = 0$  for the  $n_{01} = 13$  individuals with  $u_{0i1} = 1$  and  $d_{it} = 1$  for the  $n_{02} = 22$  individuals with  $u_{0i2} = 1$






 $\mu_{et}$ 

 $\pi_t$ 

--- Control (t = 1)--- Intervention(t = 2)

#### Cost-effectiveness analysis



Cost-Effectiveness Acceptability Curve

- A full Bayesian approach to handling missing data extends standard "imputation methods"
  - Can consider MAR and MNAR with relatively little expansion to the basic model

- A full Bayesian approach to handling missing data extends standard "imputation methods"
  - Can consider MAR and MNAR with relatively little expansion to the basic model
- · Particularly helpful in cost-effectiveness analysis, to account for
  - Asymmetrical distributions for the main outcomes
  - Correlation between costs & benefits
  - Structural values (eg spikes at 1 for utilities or spikes at 0 for costs)

- A full Bayesian approach to handling missing data extends standard "imputation methods"
  - Can consider MAR and MNAR with relatively little expansion to the basic model
- · Particularly helpful in cost-effectiveness analysis, to account for
  - Asymmetrical distributions for the main outcomes
  - Correlation between costs & benefits
  - Structural values (eg spikes at 1 for utilities or spikes at 0 for costs)
- Need specialised software + coding skills
  - R package missingHE under development to implement a set of general models
  - Preliminary work available at https://github.com/giabaio/missingHE
  - Eventually, will be able to combine with existing packages (eg BCEA: http://www.statistica.it/gianluca/BCEA; https://github.com/giabaio/BCEA) to perform the whole economic analysis

# Thank you!